STOCK TITAN

ASP Isotopes (NASDAQ: ASPI) sets April 13, 2026 business update webcast

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

ASP Isotopes Inc. announced that Executive Chairman and CEO Paul Mann will host a business update conference call and webcast on April 13, 2026, at 8:00 AM ET. Investors and the public can join via toll and toll-free numbers or a live webcast, with a replay available on the company’s website.

The company develops proprietary isotope enrichment technologies, including its Aerodynamic Separation Process and Quantum Enrichment, to supply critical materials for nuclear medicine, advanced semiconductors, and nuclear energy. The announcement also highlights that management may discuss forward-looking statements during the call, which are subject to significant risks and uncertainties.

Positive

  • None.

Negative

  • None.
Conference call date April 13, 2026 Business update conference call schedule
Conference call time 8:00 AM ET Start time for business update call
USA toll dial-in +1.646.968.2525 Conference call access number for USA / International
USA toll-free dial-in +1.888.596.4144 Toll-free access number for U.S. participants
Canada Toronto dial-in +1.647.495.7514 Conference call access number for Toronto, Canada
Conference ID 5073116 ID required to join the ASP Isotopes call
forward-looking statements regulatory
"Such statements are considered “forward-looking statements” within the meaning of the safe harbor provisions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
safe harbor provisions regulatory
"within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995"
Safe harbor provisions are rules or legal protections that shield companies or individuals from certain penalties or liabilities when they follow specific guidelines or procedures. They provide a sense of security, encouraging compliance and innovation by reducing the fear of legal repercussions if they act in good faith. For investors, these provisions help ensure that companies are transparent and accountable without the risk of unfair punishment for honest mistakes.
Aerodynamic Separation Process technical
"The Company’s proprietary technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment"
Quantum Enrichment technical
"the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment (“QE technology”), are designed to enable the production"
isotope enrichment facilities technical
"ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, focused on the enrichment"
nuclear medicine technical
"critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy"
Nuclear medicine uses very small amounts of radioactive substances to create images of the body or deliver targeted treatments; think of it like a tracer dye that lights up organs on a scan or a guided missile that seeks out and treats diseased tissue. It matters to investors because technological advances, regulatory approvals, and clinical adoption directly affect sales of specialized drugs, imaging equipment, and hospital services, influencing revenue, growth prospects, and regulatory risk for healthcare companies.

EXHIBIT 99.1

 

ASP Isotopes to Host Business Update Conference Call on April 13, 2026, at 8:00 AM ET

 

DALLAS, April 10, 2026 -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today announced that Paul Mann, Executive Chairman and Chief Executive Officer at ASP Isotopes, will host a business update conference call and webcast on Monday, April 13, 2026, at 8:00 AM ET.

 

Dial-in Information

 

USA / International Toll: +1.646.968.2525

USA - Toll-Free: +1.888.596.4144

Canada - Toronto: +1.647.495.7514

Canada - Toll-Free: +1.888.596.4144

Conference ID 5073116 and press #

 

Investors and the general public are invited to listen to a live webcast at: https://events.q4inc.com/attendee/430022486

 

A replay of the webcast will be available at www.aspisotopes.com approximately three hours after the conference call concludes.

 

About ASP Isotopes

 

ASP Isotopes is an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. The Company’s proprietary technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment (“QE technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology applications. ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, focused on the enrichment of low atomic mass elements, or light isotopes. For more information, please visit www.aspisotopes.com.

 

 

1

 

 

Forward-Looking Statements

 

During the business update conference call, members of management may make statements that provide information other than historical information. Such statements are considered “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to: the impact of the conflict in the Middle East and the closure of the Strait of Hormuz on the helium market; the anticipated progress and timing for completion of Phase 1 and 2 of the Renergen helium project; the ability to fund completion of the development of the Renergen helium project; anticipated production quantities and supply of helium and LNG upon completion of Phase 1 and 2 of the Renergen helium project; projections about the future nuclear fuel cycle for advanced nuclear reactors and fusion systems; the future of the company’s enrichment technologies as applied to uranium enrichment; the outcome of the company’s initiative to commence enrichment of uranium in South Africa and the company’s discussions with nuclear regulators in South Africa, the United States or the United Kingdom; the outcome of QLE’s collaboration with The South African Nuclear Energy Corporation (Necsa); the commencement of research, development and production activities in the United States or the United Kingdom; QLE’s anticipated growth strategies and anticipated trends in QLE’s business; statements relating to QLE’s strategic partnerships or commercial initiatives and relationships with Fermi America, TerraPower and Necsa; anticipated production quantities and supply of enriched isotopes to customers; and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of enriched isotopes or helium and LNG, future performance under contracts, and our strategies for product development or extraction of resources, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including, but not limited to: the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our future capital requirements and sources and uses of cash; our ability to obtain funding for our operations and future growth; whether we succeed in obtaining permissions and regulatory approvals required to test and develop our enrichment technologies on uranium in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. “Risk Factors” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. All forward-looking statements are qualified by reference to the cautionary statements set forth herein and should not be relied upon.

 

Contact

IR@ASPIsotopes.com

 

 

2

 

FAQ

When is ASP Isotopes’ (ASPI) business update conference call scheduled?

ASP Isotopes’ business update conference call is scheduled for April 13, 2026, at 8:00 AM ET. The event will feature Executive Chairman and CEO Paul Mann and will be accessible to investors and the general public via phone dial-in and live webcast.

How can investors access the ASP Isotopes (ASPI) April 13, 2026 webcast?

Investors can access the webcast at https://events.q4inc.com/attendee/430022486 during the April 13, 2026, 8:00 AM ET call. A replay will be available approximately three hours after the conference concludes on the company’s website at www.aspisotopes.com for later listening.

What does ASP Isotopes (ASPI) focus on in its core business?

ASP Isotopes focuses on developing a differentiated isotope enrichment platform for critical materials. Its technologies support nuclear medicine, next-generation semiconductors, and nuclear energy, using proprietary Aerodynamic Separation Process and Quantum Enrichment systems at enrichment facilities in Pretoria, South Africa.

What are the main technologies used by ASP Isotopes (ASPI) for isotope enrichment?

ASP Isotopes uses its proprietary Aerodynamic Separation Process (ASP technology) and Quantum Enrichment (QE technology). These platforms are designed to produce enriched isotopes for industrial and advanced technology applications, particularly low atomic mass, or light, isotopes used across several critical sectors.

What forward-looking statements might ASP Isotopes (ASPI) discuss on the call?

Management may discuss forward-looking statements about business strategies, enrichment technologies, helium and LNG projects, regulatory approvals, and future revenue prospects. These statements reflect current expectations, not guarantees, and are subject to numerous risks and uncertainties that could cause materially different outcomes.

Why does ASP Isotopes (ASPI) include a forward-looking statements caution?

ASP Isotopes includes a forward-looking statements caution to remind listeners that non-historical comments involve significant risks and uncertainties. Actual results may differ materially due to regulatory, funding, operational, market, and geopolitical factors described in the company’s risk factor disclosures and SEC reports.

Filing Exhibits & Attachments

6 documents